the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

NCT02737085 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

BIOLOGICAL: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells

Sponsor

Southwest Hospital, China